New initiatives for LENVIMA®

New initiatives for LENVIMA®

Grupo Biotoscana announces new initiatives for LENVIMA®.

Montevideo, Uruguay March 12, 2018. BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces that, last week, our partner, Eisai Co., Ltd., announced a separate arrangement for our key partnered drug LENVIMA® (lenvatinib).

Under a new agreement between Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A (known as MSD outside the United States and Canada), Eisai and MSD co-develop and co-commercialize LENVIMA® (lenvatinib mesylate), as monotherapy and in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

GBT reinforces its commitment to commercialize LENVIMA® (lenvatinib) and clarifies that the arrangement between Eisai and MSD does not change, GBT’s rights to LENVIMA® (lenvatinib), which were the subject of a previous agreement between GBT and Eisai, and GBT will continue to book 100% of the sales of LENVIMA® (lenvatinib) in GBT‘s territory.

About GBT-Grupo Biotoscana
GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, LKM and DOSA. GBT’s strong portfolio combines world-class licenses and proprietary products. To find out more, please visit www.grupobiotoscana.com.

About LENVIMA 
LENVIMA® (lenvatinib) is a novel multiple receptor tyrosine kinase inhibitor (orally administered molecular-targeted agent) discovered and developed by Eisai. Launched as a treatment for refractory thyroid cancer in the United States, Japan and Europe in 2015 and has been granted orphan drug status (a drug for rare diseases) for the treatment of thyroid cancer by the regulatory authorities in each of these regions. LENVIMA® is also indicated to treat adults with a form of advanced kidney cancer.